Topics

Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS

03:44 EDT 13 Sep 2019 | Pharmafile

Johnson & Johnson subsidiary Janssen have announced results from its Phase 3 OPTIMUM trial showing superior efficacy to Sanofi’s Aubagio (teriflunomide) with its investigational drug ponesimod in adults with relapsing multiple sclerosis (MS).

In the two year head-to-head trial the S1P1 receptor modulator ponesimod demonstrated superiority on primary endpoints and most secondary endpoints.

read more

Original Article: Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS

NEXT ARTICLE

More From BioPortfolio on "Janssen’s Ponesimod outclasses Sanofi’s Aubagio in relapsing MS"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...